Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncolytic Virus Plus Camrelizumab and Chemotherapy for Pancreatic Cancer
NCT06346808Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- May 2024
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic cancer (PC), sponsored by Sichuan University. Primary endpoint: Incidence of Treatment-Related Adverse Events at 1 year. Planned start May 2024; status: not yet recruiting.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06346808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346808.